selected publications

• letter

  • Current bioequivalence criteria are adequate for oral cyclosporin A formulations [1].  Therapeutic Drug Monitoring. 722-723. 1998-01-01

• article

  • Environmental exposure to arsenic and chromium in children is associated with kidney injury molecule-1.  Environmental Research.  150:653-662. 2016-01-01
  • Global gene expression changes in human urothelial cells exposed to low-level monomethylarsonous acid.  Toxicology.  291:102-112. 2012-01-01
  • Decreased cyclosporine exposure during the remission of nephrotic syndrome.  Pediatric Nephrology.  22:84-90. 2007-01-01
  • Increased cyclosporine bioavailability induced by experimental nephrotic syndrome in rats.  Canadian Journal of Physiology and Pharmacology.  85:502-506. 2007-01-01
  • Limited sampling model for area-under-the-curve monitoring in pediatric patients receiving either Sandimmune® or Neoral® cyclosporin A oral formulations.  Pediatric Transplantation.  3:225-230. 1999-01-01
  • Bioavailability of two oral formulations of cyclosporin A in uremic children before renal transplantation.  Pediatric Transplantation.  2:145-149. 1998-01-01
  • Unavailability of two oral formulations of cyclosporin a in uremic children awaiting renal transplantation.  Proceedings of the Western Pharmacology Society.  41:281-. 1998-01-01